The study, led by Roksana Gozdowska and Marek Kuch together with colleagues at the Medical University of Warsaw and collaborating institutions, focused on circulating microRNAs, tiny fragments of non-coding RNA that drift through the bloodstream inside membrane-wrapped vesicles or bound to carrier proteins. MicroRNAs are short molecules, roughly 18 to 25 nucleotides long, that never get translated into proteins. Instead, they act as fine-tuners of gene expression: each microRNA can bind to matching sequences on messenger RNA transcripts and suppress their translation or trigger their degradation. Because a single microRNA can regulate dozens of target genes, and because their levels change in response to tissue injury, inflammation and stress, they have become prime suspects in the search for biomarkers that capture complex biological processes such as cardiac healing.

To find out whether these molecules could flag patients destined for recovery, the researchers enrolled 39 patients who had just experienced their first myocardial infarction. Everyone in the cohort completed a structured cardiac rehabilitation program, the standard supervised combination of exercise training and lifestyle support given after a heart attack. The team then applied strict echocardiographic criteria to define who had achieved reverse remodeling by the eight-week follow-up: either an absolute increase in left ventricular ejection fraction of at least 10 percentage points, or a reduction in left ventricular end-systolic volume of at least 15 percent. Ejection fraction measures the proportion of blood the ventricle ejects with each beat, while end-systolic volume reflects how much blood remains in the chamber after contraction, so together they capture both the pumping strength and the size of the recovering ventricle.

From the original cohort, ten patients who met the reverse remodeling criteria were matched with ten patients whose left ventricular status remained stable over the same period. The twenty analyzed patients had a mean age of 57 years, with a standard deviation of nine years. At baseline, before rehabilitation began, the two groups looked meaningfully different on standard imaging: the stable group started with a significantly higher ejection fraction of 53 percent, compared with 44 percent in the group that would go on to recover, a difference that reached statistical significance with a p-value of 0.013. That starting gap makes the subsequent recovery all the more notable, because the patients who improved began from a weaker position.

The echocardiographic follow-up added a second layer of evidence. Regional contractility impairment, meaning localized areas of the ventricular wall that move abnormally because of infarct damage, was present in all of the patients who later achieved reverse remodeling. By the eight-week mark, 70 percent of those patients had reversed this regional dysfunction, their previously stunned or hibernating heart muscle segments regaining movement. This pattern suggests that a substantial share of early post-infarction dysfunction is not permanent cell death but recoverable injury, and that the patients who recover are those whose hearts successfully re-activate this dormant tissue during rehabilitation.

The molecular heart of the study lay in the blood samples. Using quantitative reverse transcription polymerase chain reaction, a technique that amplifies and measures specific RNA sequences with high sensitivity, the team quantified 375 circulating microRNAs in each patient at baseline. They then searched for molecules that were more abundant in the patients who would later recover, reasoning that a higher starting level of a recovery-associated microRNA might act as an early signal of a heart poised to heal. This screen yielded fourteen candidate biomarkers: miR-15b-5p, miR-24-3p, miR-29c-3p, miR-99b-5p, miR-127-3p, miR-146a-5p, miR-199a-3p, miR-361-5p, miR-502-5p, miR-625-5p, miR-376c-3p, miR-18b-5p, miR-342-5p and miR-429. Several of these, including miR-502-5p, miR-376c-3p and miR-18b-5p, had not previously been implicated in human cardiac reverse remodeling, making them genuinely novel candidates.

Identifying the microRNAs was only the first step; the researchers also wanted to know what these molecules might actually be doing. Because individual microRNAs repress many target genes, the team performed enrichment analysis, a computational method that asks whether the genes targeted by a set of microRNAs cluster within particular biological pathways more often than chance would predict. The analysis pointed squarely at four major signaling networks: the PI3K-Akt pathway, the MAPK cascade, FoxO signaling and HIF-1 signaling. These are not obscure corners of cell biology. PI3K-Akt is a central pro-survival route that protects heart muscle cells from programmed death and drives growth and metabolism; MAPK pathways transmit stress and growth signals from the cell surface to the nucleus; FoxO transcription factors govern cell survival, autophagy and oxidative stress responses; and HIF-1 is the master regulator of the cellular response to low oxygen, a condition the infarcted heart knows intimately.

The convergence of the fourteen candidate microRNAs on these pathways paints a coherent biological picture. A heart recovering from an infarction must simultaneously limit further cell death, clear damaged tissue, stimulate repair, and re-vascularize oxygen-starved regions, and each of the enriched pathways contributes to one or more of those tasks. Circulating microRNAs, in this framing, are not merely passive debris shed from injured tissue; they are potentially active participants in intercellular communication, capable of being delivered to recipient cells and shifting gene expression programs there. If baseline microRNA profiles genuinely reflect the heart’s reparative capacity, a simple blood draw taken days after a heart attack could eventually help clinicians identify which patients are most likely to benefit from intensive rehabilitation and which need closer surveillance or additional therapies.

The authors are careful to frame the work as a bridge between laboratory findings and clinical practice rather than a definitive answer. Preclinical studies in cell cultures and animal models have long implicated microRNAs in cardiac remodeling, but translating those findings to patients has been difficult, partly because human heart attack patients are heterogeneous in age, infarct size, medication and comorbidities. By measuring microRNAs directly in patients and linking them to objectively defined echocardiographic outcomes, the study connects preclinical biology to real clinical settings. At the same time, the sample size is small, with only twenty patients in the final matched analysis, and the candidate biomarkers were identified in a pooled discovery design. The authors themselves emphasize that validation in larger, independent, non-pooled cohorts is essential before any of these molecules could move toward clinical use as a diagnostic or prognostic test.

Even with those caveats, the study adds an appealing piece to one of cardiology’s most consequential puzzles. Reverse remodeling after a heart attack represents the heart’s innate capacity for self-repair, a capacity that varies dramatically between patients for reasons that remain poorly understood. If a panel of fourteen circulating microRNAs, measured from a routine blood sample, can flag that capacity early, it could reshape how patients are triaged after infarction, personalize rehabilitation programs, and even identify candidates for emerging regenerative therapies. It would also reinforce a broader shift in medicine toward liquid biopsies, in which molecular signals circulating in blood replace or complement invasive and imaging-based assessments. For now, the fourteen microRNAs remain candidates rather than validated tools, but they offer a molecular fingerprint of cardiac recovery and a concrete starting point for the larger studies that will determine whether that fingerprint can be read reliably at the bedside.

Subject of Research: Circulating microRNAs as candidate biomarkers of left ventricular reverse remodeling after myocardial infarction

Article Title: Circulating microRNAs as potential candidate biomarkers of left ventricular reverse remodeling after myocardial infarction: A pilot study

Article References: Gozdowska, R., Konopka, M., Hojka-Osińska, A., Jas, G., Czarzasta, K., Cudnoch-Jędrzejewska, A., Braksator, W., Klimczak-Tomaniak, D., & Kuch, M. (2026). Circulating microRNAs as potential candidate biomarkers of left ventricular reverse remodeling after myocardial infarction: A pilot study. PLOS One, 21(10), e0360414. https://doi.org/10.1371/journal.pone.0360414

Image Credits: AI Generated

DOI: 10.1371/journal.pone.0360414

Keywords: microRNAs, myocardial infarction, left ventricular reverse remodeling, biomarkers, cardiac rehabilitation, echocardiography, ejection fraction, PI3K-Akt pathway, MAPK, FoxO signaling, HIF-1, non-coding RNA

The marker in question is SPOCK1, also known as testican-1, a heparan sulfate and chondroitin sulfate proteoglycan first identified in human seminal plasma. SPOCK1 is an extracellular matrix protein with multiple functional domains, and when overexpressed in various cancers, it has been shown to promote cell cycle progression and tumor cell growth by upregulating the PI3K/AKT signaling pathway. It has also been implicated in elevated invasion and migration in gastric cancer, glioma, pancreatic cancer, and prostate cancer. Recent studies have highlighted its role in activating cell migration and matrix metalloproteinases, which can support epithelial-to-mesenchymal transition, or EMT, a process by which cancer cells gain motility and invasive properties.

The research group, led by Tibor Krenacs and Kornel Danos, had previously demonstrated in mouse, rat, and human liver models that SPOCK1 is upregulated during hepatocarcinogenesis, with high levels observed in hepatocellular carcinomas and cirrhotic liver. They also detected SPOCK1 upregulation in ovarian cancer in relation to poor disease outcome. In the oral cavity of transgenic mice, elevated SPOCK1 expression mediated EMT in a cyclosporin-A induced gingival overgrowth model, suggesting that SPOCK1 may influence the malignant transformation and progression of oral epithelial tissues. These observations prompted the team to investigate whether SPOCK1 could serve as a prognostic biomarker in HNSCC.

To test this hypothesis, the researchers employed a dual approach. First, they analyzed publicly available transcriptomic datasets of 500 HNSCC patients using the Kaplan-Meier Plotter open-source database management software. This in silico analysis revealed that SPOCK1 mRNA expression was markedly higher in oral carcinomas than in normal oral mucosa, with a log-rank p value of 5.76e-06. More importantly, elevated SPOCK1 expression was consistently associated with significantly reduced overall survival, with a hazard ratio of 1.57 and a log-rank p value of 0.001. The adverse prognostic role was particularly pronounced in tumors with high neoantigen levels, where the log-rank p value reached 0.00085, compared to tumors with low neoantigen levels, where the association was not statistically significant.

Second, the team conducted an in situ protein-level analysis on tissue samples from 97 HNSCC patients diagnosed and treated at Semmelweis University between 2012 and 2015. The cohort comprised 79 men and 18 women, with a mean age of 60.3 years. The most common anatomical location was oropharyngeal tumors, accounting for 37.1% of cases. The researchers created tissue microarrays using duplicate or triplicate cores of 2 mm diameter from representative tumor areas and performed standardized immunohistochemistry with a monoclonal mouse anti-SPOCK1 antibody. All slides were digitized using a Panoramic scan instrument equipped with a Carl Zeiss objective.

Protein expression was quantified using the H-Score system, which considers both staining intensity and the percentage of positive tumor cells. The researchers evaluated SPOCK1 expression through two independent methods: eye-control testing by three assessors and a machine-learning-based automated image analysis tool called DensitoQuant. The immunohistochemical reactions showed a characteristic granular peri- and paranuclear pattern, suggesting that SPOCK1 protein mainly localized to the Golgi region and mitochondria of tumor cells, with practically no stromal positivity. This localization is consistent with SPOCK1 being a secreted proteoglycan processed through the Golgi apparatus.

The results from both scoring approaches converged on the same conclusion. Cox regression analysis based on visual scoring demonstrated a significant association between SPOCK1 expression and overall survival, with a p value of 0.002 and a relative risk of 1.017. The log-rank test showed significant survival detriment when cases were dichotomized at the upper quartile of H-Scores, with a p value of 0.002. The machine-learning-based evaluation similarly confirmed the association, with Cox regression yielding a p value of 0.008 and the log-rank test a p value of 0.044. These findings align with the mRNA-level data and reinforce the role of SPOCK1 as a clinically relevant negative prognostic biomarker in HNSCC.

The mechanistic implications of SPOCK1 overexpression in HNSCC are speculative but grounded in pathways established in other cancers. In the majority of HNSCC cases, the PI3K-AKT pathway is activated, promoting proliferation, EMT, and tumor cell invasion. HNSCC progression has been linked to ongoing dedifferentiation toward a cancer stem cell state accompanied by partial or hybrid EMT, responsible for enhanced tumor cell migration and metastatic spreading. SPOCK1 expression has been linked to EMT support in several studies, and further evidence came from work showing that pre-miR-150 can downregulate SPOCK1 to reduce the aggressiveness of HNSCC cells. The development of an invasive EMT-prone phenotype in HNSCC can probably be mediated through the activation of TGF-β1, EGFR, and NOTCH signaling, as well as hypoxia-driven HIF-1α expression.

The clinical context of HNSCC treatment adds weight to these findings. While HPV-positive HNSCC can be prevented by vaccination, HPV-negative cases at advanced stage require multimodal radio- and chemotherapy besides surgery. Epidermal growth factor receptor-positive cases have been treated using radiotherapy combined with anti-EGFR antibodies such as cetuximab, though resistance frequently develops due to EGFR mutations. Immune checkpoint inhibitors like pembrolizumab and nivolumab have been approved in cisplatin-refractory recurrent or metastatic HNSCC. Beyond its potential prognostic role, SPOCK1 may be offered as a potential target for developing novel treatment options, particularly if reliably detected in the serum for liquid biopsy-based monitoring of residual tumors.

The researchers acknowledge the limitations of their study, including the moderate number of patients collected in a single department and the lack of complete HPV data for all cases, which prevented correlation of SPOCK1 expression with virus infection status. Whole-section versus tissue microarray validation to more accurately consider tumor heterogeneity, and validation of automated versus pathologist-read testing, might also be required. Nevertheless, the convergence of manual and algorithm-based approaches, combined with the consistency between mRNA and protein-level findings, suggests that SPOCK1 overexpression may specify a group of oral cancers with aggressive tumor biology. Further validation in larger, multicenter HNSCC cohorts accompanied by complete HPV, p16, smoking, and alcohol exposure data is needed before SPOCK1 can be reliably integrated into clinical decision-making for head and neck cancer patients.

Subject of Research: SPOCK1 overexpression suggests poor prognosis in head and neck squamous cell carcinomas

Article Title: SPOCK1 overexpression suggests poor prognosis in head and neck squamous cell carcinomas

Article References: Jakob, N. P., Majoros, M., Uri, I., Szakadati, H., Birtalan, E., Baghy, K., Kelemen, Z., Tamas, L., Danos, K., & Krenacs, T. (2026). SPOCK1 overexpression suggests poor prognosis in head and neck squamous cell carcinomas. Pathology & Oncology Research, 32, Article 1612448. https://doi.org/10.3389/pore.2026.1612448

Image Credits: AI Generated

DOI: 10.3389/pore.2026.1612448

Keywords: SPOCK1, head and neck squamous cell carcinoma, prognostic biomarker, immunohistochemistry, epithelial-to-mesenchymal transition, PI3K/AKT pathway, liquid biopsy, tissue microarray, DensitoQuant, Kaplan-Meier Plotter, HPV-negative HNSCC, overall survival

The compound, named MHO7, is the molecule 6-epi-ophiobolin G, a sesterterpenoid originally isolated from the secondary metabolites of the mangrove-derived fungus Aspergillus ustus 094,102. Sesterterpenoids are a structurally unusual class of fungal natural products built from five isoprene units, and ophiobolins in particular have attracted attention for potent and multi-pathway anticancer activity. The Wuhan group, led by Haiyan Wen, Feifei Zeng, Yu Lan and senior authors Juanjuan Li, Siqi Zhou and Kui Hong, had previously shown that MHO7 acts as an estrogen receptor alpha degrader in hormone-positive breast cancer and halts triple-negative tumor growth by inducing immunogenic cell death through the ER stress-CHOP pathway. What remained unknown was whether the compound could also stop cancer cells from physically spreading, the process that drives most breast cancer deaths.

To answer that question, the researchers used MDA-MB-231, a highly invasive, mesenchymal-like triple-negative breast cancer cell line, as their in vitro model, and a subcutaneous xenograft model in immunodeficient BALB/c nude mice for in vivo testing. In the laboratory assays, MHO7 treatment significantly reduced wound closure in scratch tests and sharply cut the number of cells that migrated or invaded through Transwell membranes, including through Matrigel-coated inserts that mimic the extracellular matrix barrier. The compound also reduced the ability of cells to attach to fibronectin-coated surfaces, a direct readout of how strongly tumor cells grip the matrix that anchors them before they crawl away.

Perhaps the most striking cellular effect involved the junctions that hold epithelial cells together. Immunofluorescence microscopy showed that MHO7 increased the accumulation of beta-catenin at E-cadherin-positive cell-cell junctions, meaning the two proteins colocalized more strongly, a sign of reinforced adherens junctions. At the same time, quantitative PCR revealed that the gene encoding E-cadherin, CDH1, was significantly upregulated, while the matrix-degrading enzymes MMP-2 and MMP-9 were downregulated. In plain terms, the compound appears to weld cancer cells more tightly to their neighbors while stripping them of the molecular scissors they use to cut through tissue, a double blow to the metastatic cascade.

To understand how MHO7 achieves this, the team re-analyzed transcriptome sequencing data from treated cells and identified 3,107 upregulated and 3,039 downregulated differentially expressed genes. When the downregulated genes were mapped onto biological pathways using KEGG and Gene Ontology enrichment analyses, the strongest signals pointed squarely at focal adhesion, regulation of the actin cytoskeleton, and adherens junctions. Network analysis of the affected genes placed PTK2, the gene encoding focal adhesion kinase, or FAK, and SRC at central nodes interconnected with upstream integrin signaling components. Western blotting confirmed the picture at the protein level: both total and phosphorylated FAK and Src dropped significantly after MHO7 treatment.

FAK is a non-receptor tyrosine kinase that sits at the intersection of cell-matrix interactions and integrin signaling, governing survival, motility and invasion. Its activation begins with autophosphorylation at tyrosine 397, an indispensable event that recruits and activates Src family kinases, which then drive cytoskeletal remodeling and downstream survival cascades. FAK is frequently overexpressed and hyperactivated in aggressive malignancies, and in triple-negative breast cancer it orchestrates invasion, chemoresistance and angiogenesis, in part by upregulating the vascular endothelial growth factor receptor VEGFR2. MHO7 treatment suppressed exactly the initiating steps of this axis, reducing p-FAK at Y397 and p-Src at Y419 both in cultured cells and in tumor tissue from treated mice.

The cytoskeletal consequences were visible under the microscope. Control MDA-MB-231 cells displayed the classic invasive morphology, with well-organized, prominent F-actin stress fibers traversing the cytoplasm. After MHO7 exposure, that architecture collapsed into profound disorganization, and in tumor tissues the adhesion scaffold protein paxillin showed disrupted localization alongside severe F-actin disarray. Downstream, the PI3K/AKT cascade, a major effector of FAK, was also quieted, with reduced phosphorylation of both PI3K and AKT confirmed by Western blot and immunohistochemistry. The compound also promoted tumor cell apoptosis, shown by increased cleaved caspase-3, and curtailed angiogenesis, shown by decreased CD31, in the xenograft tumors.

One of the study’s most intriguing findings concerns the crosstalk between FAK and the canonical Wnt/beta-catenin pathway, a bidirectional oncogenic partnership that coregulates cytoskeletal reorganization, cell motility and stemness. Transcriptomic profiling of tumor tissue from mice given 50 milligrams per kilogram of MHO7 identified 1,135 upregulated and 1,090 downregulated genes, with focal adhesion and Wnt signaling both significantly enriched among the downregulated pathways. Follow-up experiments showed a dose-dependent decrease in nuclear and cytoplasmic beta-catenin, consistent with enhanced proteasomal degradation of cytoplasmic beta-catenin and a blockade of its nuclear translocation, along with upregulated GSK-3beta and E-cadherin. By simultaneously dismantling the FAK axis and draining beta-catenin out of the nucleus, MHO7 appears to sever a dual oncogenic circuit rather than a single wire.

The in vivo results add weight to the translational promise. In the xenograft model, oral MHO7 at 50 and 100 milligrams per kilogram significantly suppressed tumor volume and growth rate, with final tumor weights significantly lower than in vehicle-treated mice and tumor growth inhibition comparable to doxorubicin at 3 milligrams per kilogram. But the safety contrast was stark: doxorubicin caused three treatment-related deaths, progressive body weight loss, myocardial deformation, hepatic congestion and nuclear changes in renal and splenic cells, plus altered serum markers of kidney and heart injury. MHO7-treated mice, by contrast, gained weight steadily, showed no pathological lesions in the heart, liver, kidney, spleen, stomach or intestines, and had normal serum levels of ALT, AST, creatinine, uric acid, creatine kinase, CK-MB and lactate dehydrogenase, indicating no hepatic, renal or cardiac toxicity.

The authors are careful about the limits of their work. The data do not yet establish FAK as a direct molecular target of MHO7; the pathway suppression could stem from an unidentified upstream regulator, and rescue experiments will be needed to prove strict causality. The in vitro findings rest on a single mesenchymal-like cell line, the bell-shaped in vivo dose response, with the intermediate 50 milligram per kilogram dose performing best numerically, may partly reflect experimental variability or pharmacokinetic constraints such as gastrointestinal absorption saturation at high oral doses, and all safety data remain preclinical. The team’s next phase will map the compound’s direct binding targets, profile its pharmacokinetics comprehensively, test it in patient-derived xenografts and optimize its structure. Still, the convergence of anti-migratory, pro-junctional, pro-apoptotic and anti-angiogenic effects, delivered through a dual FAK-Wnt mechanism with a clean toxicity profile, marks MHO7 as a rare kind of lead compound: one forged in the ocean’s fungal depths that may finally give clinicians a way to stop the deadliest part of triple-negative breast cancer, its spread.

Subject of Research: A marine-derived sesterterpenoid that inhibits triple-negative breast cancer cell migration and invasion via suppression of the FAK signaling pathway

Article Title: A marine-derived sesterterpenoid inhibits migration and invasion of triple-negative breast cancer cells by suppressing the FAK signaling pathway

Article References: Wen, H., Zeng, F., Lan, Y., Yin, Y., Huang, Y., Hu, Y., Yin, J., Li, J., Zhou, S., & Hong, K. (2026). A marine-derived sesterterpenoid inhibits migration and invasion of triple-negative breast cancer cells by suppressing the FAK signaling pathway. Frontiers in Cell and Developmental Biology, 14, Article 1967923. https://doi.org/10.3389/fcell.2026.1967923

Image Credits: AI Generated

DOI: 10.3389/fcell.2026.1967923

Keywords: triple-negative breast cancer, MHO7, sesterterpenoid, ophiobolin, FAK signaling, cell migration, invasion, Wnt beta-catenin, marine natural products, metastasis, PI3K AKT pathway, xenograft model

The study, published in Food Science & Nutrition, was framed around the concept of medicine-food homology, a principle embedded in Chinese regulatory practice that classifies certain botanicals, including ginseng, as substances traditionally used as both food and medicine. In China, ginseng is officially listed in the medicine-food homology catalogue, permitting its use as a common food ingredient in soups, teas, beverages, and functional food products. The content of ginsenoside Rb1 in cultivated ginseng varies considerably with growing conditions, ranging from 2.22 to 11.22 milligrams per gram, but its long history of safe dietary exposure is precisely what makes it attractive as a candidate for nutrition-based cancer prevention rather than conventional pharmacology.

To identify the active substance responsible for the anti-pancreatic-cancer effects of a ginseng-containing herbal formula developed by the group, the researchers first applied ultra-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. This profiling step singled out ginsenoside Rb1 as a core bioactive component, prioritized over other ginsenosides such as Rg1, Re, and Rg3 because of its high abundance in ginseng, its favorable safety profile as a food-derived saponin, and its documented antitumor and immunomodulatory activities. The team then deployed a network pharmacology screen, integrating three target-prediction platforms with five pancreatic cancer disease-target databases, to narrow the field of candidate mechanisms.

The computational pipeline was ambitious in scope. It identified 587 candidate targets for ginsenoside Rb1 and 905 pancreatic cancer-related targets, with intersection analysis revealing 110 shared targets. The resulting protein-protein interaction network contained 491 nodes and 3,728 edges, and topology analysis based on degree, betweenness, and closeness centrality surfaced a set of hub genes including STAT3, AKT1, CASP3, BCL2, HIF1A, MTOR, and SRC. KEGG enrichment analysis ultimately locked the PI3K-AKT signaling pathway as the priority candidate for experimental validation, a hypothesis the team then carried into the laboratory.

The in vivo evidence came from an orthotopic pancreatic cancer model established by inoculating KPC-derived cancer cells directly into the pancreas of C57BL/6 mice. Mice were randomly assigned to five groups receiving saline, the chemotherapy drug gemcitabine, or ginsenoside Rb1 at 25, 50, or 100 milligrams per kilogram per day. The results were striking: ginsenoside Rb1 reduced tumor growth in a dose-dependent fashion, with the high-dose group achieving efficacy comparable to gemcitabine. Ki67 staining confirmed reduced tumor cell proliferation, and high-dose treatment prolonged survival without any obvious loss of body weight, a signal that the compound was well tolerated at therapeutic doses.

Metastasis, the process that makes pancreatic cancer so deadly, was also blunted. In a syngeneic liver metastasis model, ginsenoside Rb1 treatment reduced liver metastatic burden, as shown by smaller tumor-invading areas, fewer metastatic lesions on histological staining, and a lower liver-to-body weight ratio. Immunohistochemistry revealed that the compound suppressed the expression of metastasis-related epithelial-mesenchymal transition markers, including Zeb-1 and Vimentin, in the liver lesions. Together with the primary tumor data, these findings suggested that ginsenoside Rb1 acts on more than just the cancer cells themselves.

That suspicion hardened into the study’s central insight when the researchers turned to the tumor microenvironment. Although ginsenoside Rb1 showed only limited direct cytotoxicity against pancreatic cancer cell lines and no toxicity toward normal pancreatic ductal epithelial cells, it produced dramatic changes in the immune landscape of the tumors. Multiplex immunofluorescence revealed that macrophages were a major immune population in pancreatic tumor tissue, and the most notable change after treatment was a dose-dependent reduction in M2-like macrophage markers, including CD206, CD163, and ARG1. Flow cytometry of tumor-infiltrating cells confirmed that ginsenoside Rb1 selectively decreased ARG1-positive CD11b-positive F4/80-positive M2 macrophages while leaving CD86-positive M1 macrophages untouched, indicating a selective suppression of the pro-tumoral polarization program rather than a wholesale depletion of macrophages.

The mechanism was traced to the PI3K-AKT pathway. Western blotting showed that ginsenoside Rb1 reduced phosphorylation of PI3K and AKT in a dose-dependent manner in both tumor tissues and macrophages, and molecular docking with AutoDock Vina suggested stable binding of the compound to AKT1 and PIK3CA with strong binding energies. In cell culture, the team generated M2-like macrophages from both THP-1 cells and human peripheral blood monocytes, and found that ginsenoside Rb1 had minimal effects on unpolarized macrophages but reduced the induction of M2 markers such as CD206, CD115, and TGFB1 in both models. The compound, in other words, appears to intervene at the point where resting macrophages are being converted into tumor-supporting ones.

Functional assays drove the point home. Conditioned medium from ginsenoside Rb1-treated M2-like macrophages reduced the growth of a patient-derived pancreatic tumor organoid compared with medium from untreated M2 macrophages, suggesting that the reprogrammed macrophages had lost much of their tumor-promoting activity. In a complementary in vivo test, KPC-derived pancreatic cancer cells were co-injected with either untreated or ginsenoside Rb1-treated M2-like macrophages into C57BL/6 mice, and the co-injection of treated macrophages was associated with reduced metastatic burden. Safety evaluations reinforced the compound’s tolerability: major organs showed no gross abnormalities, serum markers of liver and kidney function, including ALT, AST, BUN, creatinine, and uric acid, remained unchanged, and hepatic expression of pro-inflammatory cytokines such as TNF-alpha, IFN-gamma, and IL-6 was not significantly altered.

The authors are careful about the limits of their evidence. The study does not establish definitive causality between PI3K-AKT inhibition and macrophage modulation, which would require pathway rescue or genetic gain-of-function experiments. Tumor-associated macrophage characterization relied on conventional M2-associated markers that cannot fully resolve the heterogeneity of these cells in pancreatic cancer, and only one patient-derived organoid line was used, so inter-patient variability remains untested. Critically, the compound was administered intraperitoneally, meaning that oral bioavailability, gut microbiota-mediated deglycosylation to compound K, food-matrix effects, and processing stability all require separate investigation before ginsenoside Rb1 can be developed as a functional food ingredient or nutritional adjuvant. Standardization, toxicological evaluation, and GRAS determination also lie ahead. Still, the work offers a compelling proof of concept: a dietary botanical constituent with centuries of safe human consumption can engage tumor-immune signaling in a way that is compatible with long-term nutritional intervention, opening a preventive, low-toxicity avenue against one of medicine’s most intractable cancers.

Subject of Research: Ginsenoside Rb1 from Panax ginseng reprograms tumor-associated macrophages via PI3K-AKT signaling to suppress pancreatic cancer progression

Article Title: Ginsenoside Rb1 From the Functional Food Panax ginseng Suppresses Pancreatic Cancer Progression via Macrophage Reprogramming Through the PI3K‐AKT Pathway

Article References: Dong, C.-S., Wang, G., Niu, Y., Sun, X., Ren, W., Zhang, J., Zhang, Y., Wu, R.-X., & Wu, X. (2026). Ginsenoside Rb1 From the Functional Food Panax ginseng Suppresses Pancreatic Cancer Progression via Macrophage Reprogramming Through the PI3K ‐ AKT Pathway. Food Science & Nutrition, 14(10), Article e72468. https://doi.org/10.1002/fsn3.72468

Image Credits: AI Generated

DOI: 10.1002/fsn3.72468

Keywords: ginsenoside Rb1, Panax ginseng, pancreatic cancer, macrophage polarization, PI3K-AKT pathway, tumor microenvironment, medicine-food homology, functional food, liver metastasis, network pharmacology, immunomodulation, patient-derived organoids

The research team, led by Baohua Jiang and Ke Li of the People’s Hospital of Suzhou New District, began not in the animal facility but in the public data repositories. They downloaded the GSE128240 microarray dataset from the Gene Expression Omnibus, a database maintained by the National Center for Biotechnology Information, and used it to identify genes whose expression differs between healthy ovarian tissue and tissue affected by ovarian insufficiency. The analysis yielded 1,816 differentially expressed genes, a strikingly large molecular signature that underscores how profoundly ovarian failure remodels the transcriptome of the organ. Rather than treating these genes as an undifferentiated list, the investigators clustered them into co-expression modules and focused on the most significant ones, reasoning that genes acting together are more likely to represent genuine disease biology than isolated statistical hits.

To interpret the biology hidden in those modules, the team turned to two of the standard workhorses of computational genomics: Gene Ontology and the Kyoto Encyclopedia of Genes and Genomes, known universally as GO and KEGG. These databases map individual genes onto curated biological processes, cellular components and signaling cascades, allowing researchers to ask whether a set of co-regulated genes is enriched for particular functions. In this case, the enrichment analyses pointed to two dominant themes. The first was the PI3K-Akt signaling pathway, a canonical survival cascade that promotes cell growth, metabolism and resistance to apoptotic signals, and which has previously been implicated in granulosa cell maintenance. The second was ovarian steroidogenesis, the enzymatic machinery by which the ovary converts cholesterol into estradiol and other sex steroids. Together, the two enriched categories suggested that ovarian failure involves both a loss of cell survival signaling and a collapse of the endocrine function that depends on healthy follicular cells.

With the bioinformatic roadmap in hand, the researchers moved to the experimental phase. They established a mouse model of premature ovarian failure by administering cyclophosphamide, a chemotherapy agent that preferentially damages proliferating granulosa cells and primordial follicles, thereby mimicking the gonadotoxicity seen in young cancer patients. Once the model was established, the mice received mouse bone marrow mesenchymal stem cells, or mBMSCs, over a four-week treatment period. Mesenchymal stem cells are multipotent stromal cells that can be isolated from bone marrow and expanded in culture; they are prized in regenerative medicine not primarily because they replace lost tissue, but because they secrete trophic and immunomodulatory factors that coax damaged environments toward repair. The four-week window was chosen to allow sufficient time for the cells to exert their paracrine effects on the injured ovary.

The results of the treatment were assessed on three complementary fronts: histology, endocrinology and molecular pathology. Hematoxylin-eosin staining of ovarian sections revealed that the stem cell-treated mice retained significantly more follicles than their chemotherapy-only counterparts, indicating that the treatment protected or restored the structural substrate of fertility. On the hormonal level, the picture was equally clear. Concentrations of estradiol, the primary estrogen produced by the ovary, rose significantly in the mBMSC-treated animals, while follicle-stimulating hormone and luteinizing hormone, the pituitary gonadotropins that rise in a compensatory fashion when the ovary fails, fell significantly. This hormonal shift is precisely what one would expect if the ovary had regained functional capacity: a healthier ovary produces more estrogen and requires less pituitary drive to do so.

The mechanistic heart of the study lies in what the researchers found when they probed the apoptotic machinery of the treated ovaries. Using Western blotting and immunohistochemistry, they measured the levels of three proteins that sit at the center of the intrinsic apoptosis pathway: Bcl-2, Bax and Caspase-3. Bcl-2 is an anti-apoptotic guardian that preserves mitochondrial integrity, while Bax is its pro-apoptotic antagonist, promoting mitochondrial outer membrane permeabilization and the release of cytochrome c. Caspase-3, often called the executioner caspase, is the protease that ultimately dismantles the cell once the apoptotic decision has been made. In the chemotherapy-treated mice, the balance tipped decisively toward cell death: Bax and Caspase-3 levels were significantly elevated in ovarian tissue, consistent with widespread granulosa cell apoptosis driving follicle depletion.

After four weeks of mBMSC treatment, that balance shifted back. Levels of Bax and Caspase-3, which had been significantly increased by cyclophosphamide, were significantly decreased following stem cell therapy, while the anti-apoptotic Bcl-2 axis was correspondingly reinforced. The authors conclude that mouse bone marrow mesenchymal stem cells attenuate apoptosis in chemotherapy-damaged ovaries by regulating the Bcl2/Caspase3 signaling pathway, and that this regulation is the mechanism through which the cells effectively treat premature ovarian failure in the model. In other words, the stem cells appear to act less as replacement oocytes or follicles and more as pharmacological agents in cellular form, reprogramming the death-versus-survival calculus of the remaining ovarian cells so that more follicles survive the toxic insult.

The significance of this mechanistic clarity should not be understated. Stem cell therapy for premature ovarian insufficiency has accumulated a substantial body of animal evidence over the past two decades, with studies reporting benefits from adipose-derived, amniotic, endometrial and embryonic stem cell-derived mesenchymal populations, sometimes delivered with collagen scaffolds or attributed to paracrine signaling. Meta-analyses of animal models and early human case reports have suggested genuine promise. But a recurring criticism has been that the field knows that stem cells help without knowing precisely how, which complicates the design of clinical trials, the selection of the optimal cell type and dose, and the identification of which patients are most likely to benefit. By anchoring the therapeutic effect to a specific, measurable molecular pathway, the Suzhou team has provided a target that future studies can manipulate directly, for example by testing whether drugs that mimic the Bcl-2-preserving effect could substitute for cell therapy in some settings.

The study also carries a cautionary relevance beyond reproductive medicine. Cyclophosphamide-induced ovarian failure is the laboratory mirror of a real clinical problem: breast cancer treatment, systemic lupus erythematosus therapy and other cyclophosphamide-based regimens place young women at substantial risk of fertility loss. Fertility preservation strategies such as oocyte or ovarian tissue cryopreservation help some patients, but they are invasive, expensive and not always feasible before urgent cancer treatment. A therapy that could be administered after chemotherapy to rescue remaining follicles would represent a fundamentally different and more accessible approach. The finding that the PI3K-Akt pathway and ovarian steroidogenesis were the dominant enriched functions in the disease transcriptome further suggests that multiple nodes of the survival machinery could be targeted in parallel, potentially combining stem cell paracrine effects with small-molecule pathway modulators.

As with all preclinical work, the distance between mice and women remains considerable. The study used mouse bone marrow mesenchymal stem cells in a mouse model, and human translation will require demonstrating that human cells, delivered safely and reproducibly, achieve comparable pathway modulation in human ovaries. Questions about the fate of the transplanted cells, the duration of the effect, the possibility of off-target effects on residual cancer risk, and the standardization of cell preparations all await answers. Nevertheless, the study offers something the field has needed: a coherent causal chain linking a defined cell type, a defined injury model and a defined molecular mechanism to a measurable restoration of endocrine and histological ovarian function. If that chain holds up in larger and more translational models, the humble mesenchymal stem cell, harvested from bone marrow and guided by the ancient logic of the Bcl2/Caspase3 switch, may yet become a meaningful option for women facing chemotherapy-induced ovarian failure.

Subject of Research: Mesenchymal stem cell therapy for chemotherapy-induced premature ovarian failure via the Bcl2/Caspase3 apoptosis pathway

Article Title: Mouse Bone Mesenchymal Stem Cells Attenuate Apoptosis by Regulating the Bcl2/Caspase3 Signaling Pathway in Premature Ovarian Failure

Article References: Jiang, B., Li, K., Zhang, L. L., Zhang, S. S., Wang, J. J., & Jin, L. (2026). Mouse Bone Mesenchymal Stem Cells Attenuate Apoptosis by Regulating the Bcl2/Caspase3 Signaling Pathway in Premature Ovarian Failure. Reproductive Sciences. https://doi.org/10.1007/s43032-026-02094-8

Image Credits: AI Generated

DOI: 10.1007/s43032-026-02094-8

Keywords: premature ovarian failure, mesenchymal stem cells, Bcl2/Caspase3, apoptosis, cyclophosphamide, ovarian reserve, PI3K-Akt pathway, steroidogenesis, follicles, fertility preservation, regenerative medicine, Reproductive Sciences

The stakes are considerable. Hematopoietic stem and progenitor cells, collectively known as HSPCs, sit at the top of the blood cell hierarchy, and their sustained function underpins everything from oxygen transport to immune defense. As organisms age, HSPCs lose their regenerative power and their output skews toward the myeloid lineage, the branch that produces granulocytes and monocytes, at the expense of lymphoid cells. This myeloid skewing is accompanied by immunosenescence, the progressive deterioration of immune function that raises the incidence of cancer, cardiovascular disease, neurodegenerative disorders, and autoimmune conditions in the elderly. Previous work has shown that replacing aged HSCs with young-donor cells extends median lifespan and lowers mortality hazard in aged mice, underscoring how central the aging of this compartment is to the healthspan and lifespan of the whole organism.

ANGPTL8, also called betatrophin, RIFL, or TD26, is a secreted glycoprotein produced mainly by the liver and adipose tissue. Its expression rises after caloric intake and falls during fasting, tying it closely to feeding rhythms and to glucose and lipid metabolism. The protein is a physiological inhibitor of lipoprotein lipase, and its overexpression markedly elevates plasma triglyceride levels. Prior studies from the same group had already connected ANGPTL8 to degenerative processes: serum levels were elevated in patients with aortic dissection, the protein correlated with the grade of intervertebral disc degeneration, and in mice it promoted liver fibrosis and hepatocarcinogenesis. A clue to the new direction came from RNA sequencing of liver tissue, which unexpectedly revealed altered expression of numerous genes involved in hematopoietic differentiation when ANGPTL8 was knocked out.

To test whether ANGPTL8 influences systemic aging, the team generated ANGPTL8 knockout mice and compared them with wild-type littermates under both normal chow and high-fat diets over periods of 10 and 20 months. Quantitative PCR, Western blotting, and immunohistochemistry showed that the expression of the senescence markers P53, P21, and P16, along with components of the senescence-associated secretory phenotype, was significantly lower in the liver, lung, and spleen of knockout animals. Functional tests reinforced the molecular picture: knockout mice performed better in the Morris water maze, crossing the former platform location more often and locating it faster, and micro-CT scans of the femur revealed higher bone mineral density and bone volume fraction, suggesting protection against osteoporosis. Notably, under a high-fat diet, which stimulates ANGPTL8 secretion, knockout mice survived significantly longer than wild-type controls.

The heart of the study, however, lay in the bone marrow. Flow cytometry showed that the proportion of long-term hematopoietic stem cells, defined by the surface phenotype Lin-negative c-Kit-positive Sca-1-positive CD48-negative CD150-positive, was significantly greater in knockout mice across diet and age conditions. Cell cycle analysis revealed an increased fraction of G1-phase cells among c-Kit-positive HSPCs, indicating enhanced quiescence, a state considered essential for preserving stemness and lifelong self-renewal. In knockout HSPCs, the researchers also observed reduced levels of the cell polarity protein Cdc42 and the DNA damage marker phosphorylated gamma-H2AX, both closely associated with HSPC aging. Mitochondrial measurements added a metabolic dimension: reactive oxygen species content was markedly lower, and JC-1 probing of mitochondrial membrane potential showed less depolarization, consistent with healthier mitochondria in the absence of ANGPTL8.

Because HSPCs themselves do not express ANGPTL8, the protein must reach them through the circulation, secreted from liver and fat tissue and entering the bone marrow cavity from the blood. To model this, the team cultured sorted c-Kit-positive HSPCs with recombinant ANGPTL8 at 600 nanograms per milliliter for four days. The treated cells showed a dose-dependent rise in aging-related proteins, an increased proportion of beta-galactosidase-positive cells, a hallmark of senescence, downregulation of the proliferation marker Ki67, and elevated expression of P53, P21, P16, and SASP genes. The total number of HSPCs declined after treatment, and the cells shifted toward myeloid differentiation, producing more CD11b-positive and CD14-positive cells. Complementary assays of colony formation showed that HSPCs from knockout mice generated fewer myeloid clones, while their bone marrow contained fewer common myeloid progenitors and more common lymphoid progenitors than wild-type controls, together indicating that ANGPTL8 aggravates the myeloid bias characteristic of hematopoietic aging.

Functional consequences were tested through transplantation. Bone marrow cells from knockout or wild-type donors were injected into lethally irradiated BALB/c recipients, and early hematopoietic regeneration was assessed 15 days later. Recipients of knockout marrow showed significantly higher proportions of donor-derived hematopoietic cells, LSK HSPCs, lymphoid cells, myeloid cells, and granulocytes in both bone marrow and spleen. Conversely, when wild-type HSPCs were pre-treated with recombinant ANGPTL8 before transplantation into irradiated C57BL/6 recipients, the proportions of total hematopoietic cells, LSK cells, myeloid cells, and granulocytes were significantly reduced in recipient marrow, and lymphoid, myeloid, and granulocytic populations were diminished in the spleen. In short, exposure to ANGPTL8 impaired the regenerative and engraftment capacity of HSPCs, while its absence enhanced it.

The mechanistic thread runs through the PI3K/AKT signaling pathway, a canonical regulator of cell survival, growth, and aging. RNA sequencing of knockout and wild-type HSPCs identified the PI3K/AKT pathway as the most enriched set of differentially expressed genes, with knockout mice showing significantly upregulated pathway activity. Western blotting confirmed that the ratios of phosphorylated to total PI3K, AKT, and the downstream kinase mTOR were all elevated in knockout HSPCs and bone marrow cells, and reduced in cells treated with recombinant ANGPTL8 in vitro. Crucially, a PI3K activator, YS-49, reversed the senescence effects of recombinant ANGPTL8, lowering the percentage of beta-galactosidase-positive cells, dampening the expression of age-related molecules, and correcting the myeloid differentiation bias. This rescue experiment establishes the pathway as the functional mediator of ANGPTL8’s pro-aging action in HSPCs.

The final piece identified the receptor. Paired immunoglobulin-like receptor B, or PirB, the mouse ortholog of human LILRB2, is known to bind several angiopoietin-like proteins and is highly expressed on the HSPC membrane. Co-immunoprecipitation demonstrated that recombinant ANGPTL8 directly interacts with PirB on HSPCs, and treatment with the recombinant protein increased PirB expression. Recombinant PirB alone reduced phosphorylation of PI3K and AKT, while knocking down PirB with two distinct siRNAs not only raised PI3K/AKT phosphorylation on its own but also blocked the inhibitory effect of recombinant ANGPTL8. The authors note that PirB has independently been implicated in aging of the nervous system, where it is upregulated in the aged hippocampus and represses the PI3K/AKT/mTOR axis, suggesting a conserved role for this receptor in tissue aging that now extends to the blood-forming system.

The work carries clear translational implications, though the authors are careful about its limits. Because ANGPTL8 secretion rises after eating and caloric restriction is among the most effective anti-aging interventions in animal models, reducing ANGPTL8 through dietary approaches or direct pharmacological targeting may represent promising strategies to alleviate hematopoietic aging. The protein’s dual role in lipid metabolism adds another layer, since triglyceride accumulation is a prominent lipidomic signature of human aging and impaired lipoprotein lipase function has been shown to damage the HSPC compartment. The team acknowledges that HSPC subpopulation heterogeneity remains incompletely characterized and that the PirB mechanism, while supported by in vitro rescue and knockdown experiments, will require conditional knockout models and competitive transplantation assays for full in vivo validation. Even so, the identification of a circulating, diet-responsive metabolic protein that ages blood stem cells through a defined receptor-pathway axis offers a concrete new target in the effort to keep the aging immune system younger for longer.

Subject of Research: The role of ANGPTL8 in inducing senescence of hematopoietic stem and progenitor cells via PirB-mediated inhibition of PI3K/AKT signaling

Article Title: ANGPTL8 induces the aging of hematopoietic stem/progenitor cells

Article References: Chen, M., Zhang, M., Mei, H., Bai, X., Wang, X., Tang, Y., Jiang, H., Zhang, L., Zhou, C., & Yuan, Y. (2026). ANGPTL8 induces the aging of hematopoietic stem/progenitor cells. Biogerontology, 27(5), Article 174. https://doi.org/10.1007/s10522-026-10517-x

Image Credits: AI Generated

DOI: 10.1007/s10522-026-10517-x

Keywords: ANGPTL8, hematopoietic stem cells, aging, cellular senescence, PI3K/AKT pathway, PirB, myeloid skewing, immunosenescence, SASP, bone marrow, mitochondrial ROS, caloric restriction

The central finding is a tight quantitative link between oxidative stress, mitochondrial failure, and apoptosis. When the researchers pooled their measurements across four cancer cell lines, they found that reactive oxygen species levels correlated strongly with cell death, but that mitochondrial membrane depolarization was an even better predictor of apoptosis. Linear regression showed that roughly 88.5 percent of the variation in apoptotic response could be explained by the degree of mitochondrial depolarization alone. Once the researchers statistically adjusted for mitochondrial damage, the direct association between reactive oxygen species and apoptosis largely disappeared, suggesting that mitochondrial dysfunction sits downstream of oxidative stress and functions as the critical gatekeeper on the road to programmed cell death.

The experimental work covered an unusually broad panel of cell types: breast adenocarcinoma (MCF-7), lung adenocarcinoma (A549), colorectal carcinoma (HCT116), and cervical carcinoma (HeLa) cancer cells, alongside immortalized human keratinocytes (HaCaT) as a healthy control. The results were not uniform. Karanjin killed MCF-7, A549, and HCT116 cells in a dose- and time-dependent fashion, with the IC50 value for A549 cells falling from 65.4 micromolar at 24 hours to 39.5 micromolar at 72 hours, indicating growing potency with prolonged exposure. HeLa cells, by contrast, were remarkably resistant, showing little response even at the highest concentration of 100 micromolar after three days. Healthy HaCaT keratinocytes were essentially untouched, with viability remaining above 75 percent across all tested concentrations and durations.

The reactive oxygen species data told a consistent story. A549 cells treated with 100 micromolar karanjin produced intracellular ROS levels 1.97-fold higher than untreated controls at 24 hours, climbing to 2.45-fold by 72 hours. HCT116 cells showed increases ranging from 1.72- to 2.32-fold over the same period. HeLa and HaCaT cells generated far less oxidative stress, which the authors interpret as the key to their survival. Cancer cells typically live with elevated baseline ROS and compensate with robust antioxidant systems, including superoxide dismutase, glutathione, and thioredoxin reductase. The study found that karanjin depleted these defenses in the susceptible lines: after 50 micromolar treatment, A549 cells lost approximately 43.7 percent of their glutathione and 26.9 percent of their superoxide dismutase activity, while lipid peroxidation markers rose sharply, evidence that membranes, proteins, and DNA were being oxidatively damaged faster than the cells could repair them.

To prove that oxidative stress was genuinely driving the toxicity rather than merely accompanying it, the team pretreated cells with N-acetylcysteine, a well-established ROS scavenger. The results were decisive. In MCF-7 cells exposed to 50 micromolar karanjin, NAC pretreatment cut ROS levels from 178 percent to 122 percent of baseline and reduced lactate dehydrogenase release, a marker of membrane rupture and late-stage cell damage, from 23.4 percent to 8.2 percent, an approximately 65 percent reduction. Similar protective effects appeared in A549 and HCT116 cells, and brightfield microscopy showed that the cell-cell aggregation and morphological changes characteristic of apoptosis vanished when the antioxidant was present. HaCaT cells, which never accumulated significant ROS, retained their normal epithelial appearance under every condition tested.

Downstream of the oxidative assault, the mitochondria collapsed. Using the JC-10 fluorescent probe, the researchers measured membrane depolarization at 50 micromolar karanjin following a clear hierarchy: MCF-7 at 2.67-fold relative to control, A549 at 2.34-fold, HCT116 at 2.10-fold, and HeLa at only 1.45-fold. ATP production in the three sensitive lines fell to roughly 65 percent of control levels, consistent with damage to the electron transport chain. As the inner mitochondrial membrane lost its charge, cytochrome c escaped into the cytosol, caspase-3 activity surged, and DNA fragmentation followed. Annexin V flow cytometry confirmed the outcome: at 50 micromolar, apoptotic populations reached 36.8 percent in MCF-7, 35.0 percent in A549, and 34.5 percent in HCT116, while HeLa cells maxed out at 10.2 percent and HaCaT cells stayed between 3.2 and 5.5 percent regardless of dose.

Notably, phosphorylated NF-κB, a transcription factor often implicated in cancer cell survival and drug resistance, was not significantly altered by karanjin in any of the cell lines, ruling out one popular mechanistic hypothesis. Instead, the computational arm of the study pointed elsewhere. Network pharmacology, drawing on target prediction databases and protein-protein interaction analysis, identified nine core targets for lung cancer, including EGFR, SRC, STAT1, GRB2, and the chaperone proteins HSP90AA1 and HSP90AB1. KEGG pathway enrichment highlighted the PI3K-Akt signaling cascade, EGFR tyrosine kinase inhibitor resistance, chemical carcinogenesis via reactive oxygen species, and other cancer-related pathways. Comparative analyses across breast, colon, and cervical cancer datasets showed substantial overlap in these core targets, suggesting a common mechanism of action, with cervical cancer sharing only six of the nine hub proteins, a difference that may partly explain HeLa’s resistance.

Molecular docking with AutoDock Vina lent further support. Karanjin bound favorably to all ten cancer-related protein targets tested, with binding free energies between -6.0 and -8.3 kilocalories per mole, a range associated with stable ligand-protein interactions. The strongest predicted binding was to MEK at -8.3 kilocalories per mole, followed by mTOR at -7.9, RAF at -7.6, and RAS and PI3K at -7.4 each. These interactions, mediated through hydrogen bonds with residues such as Met 146 of MEK and Arg 348 of PI3K, suggest that karanjin could suppress the RAS/RAF/MEK/ERK and PI3K/AKT/mTOR survival cascades that cancer cells rely on for proliferation and metabolic regulation. The authors are careful to note that direct protein-level validation was beyond the scope of this work, so the docking results remain hypothesis-generating rather than conclusive.

The selectivity story comes with honest caveats. Because the IC50 for healthy HaCaT cells was never reached within the tested range, the team conservatively estimated selectivity indices using 100 micromolar as the ceiling, yielding values above 1.53 for A549, 1.36 for MCF-7, and 1.23 for HCT116 at 24 hours, all of which grew with longer exposure. Even so, these indices remain below the threshold conventionally associated with highly selective anticancer compounds, and the authors explicitly frame their findings as evidence of moderate cancer-selective activity rather than definitive tumor specificity. Karanjin’s drug-like profile, including compliance with Lipinski’s rule of five, high gastrointestinal absorption, and a predicted ability to inhibit the P-glycoprotein efflux pump implicated in multidrug resistance, keeps it interesting as a lead compound.

What makes the study methodologically notable is its integration of correlation and regression modeling with classical mechanistic assays, an approach that transforms a pile of individual measurements into a causal narrative. The data support a coherent sequence: karanjin overwhelms the antioxidant buffering capacity of susceptible cancer cells, ROS accumulates, the mitochondrial electron transport chain falters and leaks more electrons, the membrane potential collapses, and apoptosis executes in near-proportional response to the degree of depolarization. Healthy keratinocytes, with their redox systems intact, simply absorb the insult. The authors call for in-depth mechanistic evaluation and in vivo therapeutic efficacy studies to determine whether karanjin’s mitochondrial tipping point can be exploited in living tumors, a question that will determine whether this karanja tree flavonoid graduates from laboratory curiosity to genuine drug candidate.

Subject of Research: Mechanism of karanjin-induced oxidative stress, mitochondrial depolarization, and apoptosis in cancer cells

Article Title: Oxidative stress-associated mitochondrial depolarization correlates with apoptotic response in karanjin-treated cancer cells

Article References: Loo, C.-Y., Gnanaraj, C., Musa, S. H., Sivapragasam, G., Sandanamsamy, S., Siew, E. L., Yeung, S., & Lee, W.-H. (2026). Oxidative stress-associated mitochondrial depolarization correlates with apoptotic response in karanjin-treated cancer cells. Discover Chemistry, 3(1), Article 492. https://doi.org/10.1007/s44371-026-00945-6

Image Credits: AI Generated

DOI: 10.1007/s44371-026-00945-6

Keywords: karanjin, Pongamia pinnata, reactive oxygen species, mitochondrial depolarization, apoptosis, oxidative stress, cancer cells, PI3K-Akt pathway, molecular docking, network pharmacology, flavonoids, cytotoxicity

UBAP2L first attracted attention from geneticists through the patients themselves. Rare variants in the UBAP2L gene have been repeatedly identified in individuals diagnosed with neurodevelopmental disorders, including autism spectrum disorder, a condition that affects communication, social interaction, and learning in millions of families worldwide. What those human genetic findings could not establish, however, was mechanism. Correlation between a mutated gene and a disorder does not reveal whether the protein acts during embryonic brain construction, in mature neurons, or in both. The new study was designed to answer precisely that question by removing the gene selectively from the developing nervous system of laboratory mice and watching what breaks.

The team used a well-established genetic engineering strategy known as the Nestin-Cre conditional knockout system. Nestin is a marker gene active in neural stem and progenitor cells, so pairing it with the Cre recombinase enzyme allows researchers to delete Ubap2l specifically and efficiently in the embryonic nervous system while leaving the gene intact everywhere else in the body. The researchers generated two groups of animals: heterozygous mutants, called cHET, carrying one functional copy of the gene, and homozygous conditional knockouts, called cKO, in which both copies were deleted from neural tissue. This design also mirrors the human genetic situation, where many patients carry a single damaged copy.

The anatomical consequences were unambiguous. Adult cKO mice weighed significantly less than their normal littermates, and histological examination of their brains revealed a marked reduction in the number of mature cortical neurons. The cortex, the folded outer layer of the brain responsible for perception, cognition, and voluntary movement, is built in an inside-out sequence: the earliest-born neurons settle in the deepest layers while successive waves of newborn neurons migrate past them to form the outer layers. At embryonic day 18.5, near the end of gestation, the knockout mice showed abnormal cortical lamination, meaning this precisely choreographed layering had gone wrong. The blueprint of the cortex had been corrupted at its source.

Tracing the defect further back in time, the researchers examined embryos at embryonic day 14.5, the height of the cortical neurogenic period when neural progenitor cells are dividing furiously to produce the neurons that will populate the cortex. At this stage, the abundance of cortical neural progenitor cells was already reduced, and the proliferation of the remaining progenitors was impaired. In other words, the root cause of the later cortical disorganization was not a failure of neurons to migrate or survive, but a failure of the stem cell pool to expand and deliver its full quota of neurons on schedule. Fewer progenitors dividing less efficiently means fewer neurons, and fewer neurons means a thinner, mislayered cortex.

Behavioral testing translated the cellular damage into functional terms. The cKO mice exhibited impaired social interaction and deficits in learning and memory, phenotypes that resonate strongly with the diagnostic features of autism spectrum disorder and related neurodevelopmental conditions. Importantly, the cHET mice, with only one copy of the gene deleted, showed milder behavioral and cognitive impairments. This dose-sensitive pattern, where gene copy number tracks with symptom severity, is a hallmark of many neurodevelopmental disorders and strengthens the argument that the mouse model faithfully recapitulates the human condition associated with UBAP2L variants.

To understand what was happening inside the cells, the researchers performed transcriptomic profiling, sequencing the RNA of the embryonic day 14.5 cortex to measure the activity of every gene. The differentially expressed genes clustered around three biological themes: transcriptional regulation, neuronal differentiation, and cell proliferation, with proliferation-related genes predominantly downregulated. Pathway analysis sharpened the picture further, revealing dysregulation of three major signaling cascades known to steer brain development: the PI3K-AKT pathway, which controls cell growth and survival; the MAPK pathway, which transmits proliferative signals; and the Wnt pathway, a master regulator of embryonic patterning and progenitor behavior. The convergence of these three pathways on a single deleted gene suggests that UBAP2L sits at or near a hub coordinating the proliferative program of neural progenitors.

The most mechanistically revealing experiments came from direct cell-cycle analysis. By examining cell-cycle phases in the embryonic cortex and running flow cytometric analysis on UBAP2L-deficient cells in culture, the team demonstrated that loss of Ubap2l produces two distinct cell-cycle defects: the S phase, during which DNA is replicated, became abnormally shortened, and cells accumulated in the G2/M checkpoint, indicating arrest before or during mitosis. A shortened S phase raises the specter of incomplete or error-prone DNA replication, while G2/M arrest halts division altogether. Together, these defects would throttle the output of the progenitor pool exactly when the cortex can least afford it. The cell cycle, it turns out, is where UBAP2L exerts its essential function.

The rescue experiments delivered the study’s most compelling verdict. When the researchers re-introduced wild-type UBAP2L into the deficient cells, the cell-cycle defects were reversed, confirming that the phenotype was specifically caused by the absence of this protein rather than by collateral damage from the engineering process. Critically, however, UBAP2L variants associated with neurodevelopmental disorders in patients failed to rescue cell-cycle progression. This is the functional smoking gun: the very mutations found in affected individuals abolish the protein’s ability to support normal cell division, directly linking patient genetics to a concrete cellular failure mode.

The broader implications reach well beyond a single gene. UBAP2L is known to participate in RNA processing and the assembly of membraneless cellular compartments called stress granules, and this study now positions it as a bridge between the cell’s gene-expression machinery and the proliferative demands of embryonic neurogenesis. For the growing number of families carrying UBAP2L variants, the work offers a biological explanation for their children’s conditions and a defined cellular process, progenitor cell-cycle control, as a potential point of therapeutic intervention. More generally, the study adds to a compelling emerging theme in neuroscience: many autism-related genes converge not on synapses or neurotransmitters, as once assumed, but on the fundamental mechanics of how the embryonic brain builds itself, one dividing progenitor at a time.

Subject of Research: The role of the UBAP2L protein in neural progenitor proliferation, cortical development, and autism-related neurodevelopmental disorders

Article Title: Neural-specific UBAP2L deficiency causes developmental delay and cortical abnormalities in mice

Article References: Hu, M., Xie, M., Qiu, C., Peng, X., Hou, H., Zhang, S., Jia, X., Wan, Z., Guo, H., Cai, M., Hu, Z., & Tan, J. (2026). Neural-specific UBAP2L deficiency causes developmental delay and cortical abnormalities in mice. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06416-6

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06416-6

Keywords: UBAP2L, autism spectrum disorder, neurodevelopmental disorder, cerebral cortex, neural progenitor cells, cell cycle, conditional knockout mice, PI3K-AKT pathway, MAPK pathway, Wnt signaling, cortical lamination, developmental delay

Nowhere is the de-escalation philosophy more visible than in the surgical management of the axilla, the lymph node basin under the arm whose removal has historically caused lymphoedema, numbness, and chronic morbidity. Building on the legacy of the ACOSOG Z0011 trial, the SENOMAC study delivered definitive high-level evidence that patients with small primary tumors and one or two sentinel-node macrometastases can safely skip full axillary lymph node dissection. In this large cohort, omitting the dissection offered no additional benefit in recurrence-free or overall survival, firmly establishing sentinel node biopsy alone as the standard for this common scenario. Yet the commentary adds an important caveat: nearly 90 percent of patients in the sentinel-biopsy-only arm received postoperative radiotherapy, meaning the safety of the approach is contingent on access to appropriate radiation. In resource-limited settings where comprehensive radiotherapy is restricted, the direct application of the SENOMAC protocol demands caution, a point with profound implications for global health equity.

Two further trials pushed the surgical frontier even further by asking whether sentinel node biopsy itself could be abandoned in select low-risk patients. The SOUND trial showed that in women with small, clinically node-negative tumors, omitting sentinel biopsy produced non-inferior five-year distant disease-free survival compared with performing the procedure, with rates of 98.0 percent versus 97.7 percent. The larger INSEMA trial confirmed the finding in a similar population undergoing breast-conserving surgery, demonstrating no difference in five-year invasive disease-free survival. For a well-defined group of early-stage patients, axillary surgery may now be safely omitted entirely. However, the commentary notes that INSEMA left key questions unresolved: enrollment of patients with slightly larger T2 tumors was low, the precise criteria for safely skipping axillary surgery remain unclear, and the resulting uncertainty in nodal staging can complicate subsequent treatment decisions. The path forward is promising but not yet fully mapped.

In hormone receptor-positive disease, the story of the past two years has been the consolidation of CDK4/6 inhibitors in the curative setting and the urgent search for what comes after they fail. Updated results from the monarchE trial, which tested two years of adjuvant abemaciclib, confirmed a sustained and significant reduction in recurrence risk, with the absolute benefit in invasive disease-free survival reaching 7.6 percent at five years, 83.6 percent versus 76.0 percent. The NATALEE trial, testing three years of adjuvant ribociclib, expanded eligibility to a broader intermediate-to-high-risk population and demonstrated a 4.9 percent absolute improvement in four-year invasive disease-free survival, alongside a 28.5 percent reduction in the risk of distant recurrence. Notably, a subgroup analysis of node-negative patients with high-risk features, a population excluded from monarchE, showed a substantial 5.1 percent absolute benefit, effectively covering a larger proportion of Stage II patients and addressing a critical unmet need.

With CDK4/6 inhibitors now ubiquitous in first-line metastatic treatment, defining the optimal strategy after progression has become a paramount research priority, and 2024 delivered several distinct answers. The postMONARCH trial was the first to prospectively validate simply continuing a CDK4/6 inhibitor: patients who progressed on prior CDK4/6 inhibition plus endocrine therapy gained a statistically significant but modest improvement in median progression-free survival when abemaciclib was added to fulvestrant, 6.0 versus 5.3 months. The benefit appeared concentrated in patients with longer prior CDK4/6 exposure and no visceral metastases, and the small absolute gain raises questions about universal utility, but the trial provides proof of concept that continued CDK pathway inhibition can help select patients. In parallel, the EMBER-3 trial showcased the oral selective estrogen receptor degrader imlunestrant, which significantly improved progression-free survival in tumors carrying ESR1 mutations, the classic driver of aromatase inhibitor resistance. More strikingly, combining imlunestrant with abemaciclib produced clear synergistic activity, extending median progression-free survival to 9.4 versus 5.5 months overall and 9.1 versus 3.7 months in the post-CDK4/6i subgroup, positioning oral SERDs as a powerful future backbone of therapy.

Perhaps the most practice-changing development was the expansion of the antibody-drug conjugate trastuzumab deruxtecan into tumors with barely detectable HER2 expression, including the newly defined HER2-ultralow category. The DESTINY-Breast06 trial enrolled patients with hormone receptor-positive, HER2-low or HER2-ultralow metastatic disease who had progressed on endocrine therapy and compared the drug with physician’s choice of chemotherapy. Trastuzumab deruxtecan delivered a median progression-free survival of 13.2 months versus 8.1 months, with results consistent across both expression groups and an objective response rate approaching 60 percent. The trial effectively redefines a large proportion of historically HER2-negative tumors as targetable, creating a highly effective, chemotherapy-sparing option for patients whose real-world outcomes on subsequent therapy have often been less than five months. Complementing this, the PAM signaling pathway, a key resistance mechanism, became druggable in routine practice: the AKT inhibitor capivasertib doubled progression-free survival when added to fulvestrant in CAPItello-291, with even greater benefit in tumors carrying AKT pathway alterations, while the PI3Kα inhibitor inavolisib, combined with palbociclib and fulvestrant in PIK3CA-mutated disease, delivered a remarkable median overall survival of 34.0 versus 27.0 months in the INAVO120 study. Given that PAM pathway alterations occur in roughly 60 percent of Chinese patient populations, these agents represent a major step toward genuinely personalized sequencing after CDK4/6 inhibitor failure.

In HER2-positive disease, the revolution runs in both directions: less treatment for early-stage patients, more potent treatment for the metastatic setting. The WSG-TP-II trial asked whether chemotherapy could be safely omitted for so-called triple-positive tumors sensitive to both endocrine therapy and HER2 blockade. Although the chemotherapy arm achieved a significantly higher pathological complete response rate, 56.0 percent versus 23.7 percent, five-year overall survival was remarkably similar and excellent in both groups, at 97.9 percent versus 100 percent. For selected patients, a chemotherapy-free neoadjuvant regimen of endocrine therapy plus dual HER2 blockade may therefore be a viable de-escalation strategy that spares significant toxicity without compromising survival. In the metastatic setting, the PHILA trial showed that the tyrosine kinase inhibitor pyrotinib, added to trastuzumab and docetaxel, doubled median progression-free survival to 22.1 versus 10.5 months, while DESTINY-Breast09 demonstrated that first-line trastuzumab deruxtecan plus pertuzumab extended median progression-free survival to an unprecedented 40.7 versus 26.9 months, providing direct evidence for moving the antibody-drug conjugate from second line to first line. Updated DESTINY-Breast03 data cemented the drug’s second-line dominance, with median progression-free survival of 29.0 versus 7.2 months against trastuzumab emtansine and median overall survival of 52.6 months, a figure approaching first-line results from the CLEOPATRA era.

Triple-negative breast cancer, long the most feared subtype for its aggressive biology and lack of targets, finally saw both immunotherapy and precision medicine mature. Final overall survival results from KEYNOTE-522 confirmed that adding pembrolizumab to neoadjuvant chemotherapy, followed by adjuvant pembrolizumab, produced a significant five-year overall survival benefit of 86.6 percent versus 81.7 percent, regardless of PD-L1 status, cementing the regimen as the global standard of care. In China, the CamRelief trial showed that the PD-1 inhibitor camrelizumab significantly increased pathological complete response rates when added to neoadjuvant chemotherapy, 56.8 percent versus 44.7 percent, while the antibody-drug conjugate Dato-DXd showed promise in the neoadjuvant I-SPY2.2 platform. In the metastatic setting, TORCHLIGHT established toripalimab plus nab-paclitaxel as a new standard for PD-L1-positive patients in China, with progression-free survival of 8.4 versus 5.6 months.

The most revolutionary TNBC result, however, came from the FUTURE-SUPER trial, which applied the molecular Fudan Subtypes model to guide first-line therapy for metastatic disease. Patients were stratified into biologically defined groups, including luminal androgen receptor tumors with HER2 or PI3K/AKT mutations, immunomodulatory tumors, and basal-like or mesenchymal-like subgroups, and each received subtype-specific treatment rather than uniform chemotherapy. The precision arm nearly doubled median progression-free survival, 11.3 versus 5.8 months, breaking a long-standing impasse in targeted therapy for this subtype. Later-line options also expanded dramatically: the TROP2-directed antibody-drug conjugate sacituzumab tirumotecan improved progression-free survival to 5.7 versus 2.3 months over chemotherapy in OptiTROP-Breast01, and ASCENT-04/KEYNOTE-D19 showed that sacituzumab govitecan combined with pembrolizumab extended first-line progression-free survival to 11.2 versus 7.8 months in previously untreated, PD-L1-positive advanced disease, offering a novel chemotherapy-sparing option.

The commentary’s authors close with a sober assessment of what remains. The challenge ahead lies in optimally sequencing these powerful new agents, identifying predictive biomarkers to guide their use, and ensuring that transformative therapies reach all patients who stand to benefit. Global disparities in regulatory approval and the burden of financial toxicity remain critical hurdles, and the cautionary notes embedded in the surgical trials, particularly the dependence of de-escalation on radiotherapy access, underscore that scientific evidence alone cannot guarantee equitable care. Still, the trajectory is unmistakable: breast cancer treatment in 2025 is increasingly personalized, potent, and patient-centered, defined as much by what clinicians can now safely withhold as by what they can newly offer.

Subject of Research: Precision-guided de-escalation and targeted therapy advances in breast cancer treatment

Article Title: Breast cancer in 2025: navigating new horizons of precision-guided de-escalation

Article References: Wang, Z., Yang, B., & Wu, J. (2026). Breast cancer in 2025: navigating new horizons of precision-guided de-escalation. Holistic Integrative Oncology, 5(1), Article 41. https://doi.org/10.1007/s44178-026-00258-9

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00258-9

Keywords: breast cancer, de-escalation, CDK4/6 inhibitors, antibody-drug conjugates, trastuzumab deruxtecan, triple-negative breast cancer, immunotherapy, HER2-low, axillary surgery, precision medicine, SERDs, PI3K/AKT pathway

The scale of the problem is staggering. Diabetes affected about 463 million people, roughly 9.3 percent of the global population, as of 2019, and chronic hyperglycemia gradually damages nerves and blood vessels throughout the body. When peripheral nerves deteriorate, patients lose protective sensation in their feet; when blood vessels narrow, tissues are starved of oxygen and nutrients. The review notes that neuropathy is the primary cause of diabetic ulcers, with 18.7 percent of cases classified as hypoxic and 34.2 percent as neuro-hypoxic. Add in impaired immune responses, stem cell dysfunction, growth factor imbalances, and a heightened susceptibility to infection by organisms such as Staphylococcus aureus—including methicillin-resistant strains—and the result is a wound environment that stubbornly resists healing. Current treatments, from offloading pressure and wound care to growth factors, stem cell therapy, and bioengineered skin substitutes, often fail to address every stage of the healing cascade: coagulation, inflammation, proliferation, and remodelling.

Thymosin beta 4 is a compact, naturally occurring protein of just 43 amino acids, with a molecular weight of 4.9 kilodaltons, originally isolated from bovine thymus. It is highly conserved and water-soluble, found in nearly every tissue and cell type except erythrocytes. Upon injury, platelets, natural killer cells, and other cells release Tβ4, which protects against further damage, reduces programmed cell death, curbs microbial proliferation, and dampens inflammation. Mechanistically, the peptide interacts with actin to drive cell movement, promotes the differentiation of progenitor cells, epithelial cells, and keratinocytes, and stimulates the formation of new blood vessels. Crucially, it also reduces the accumulation of myofibroblasts at wound sites, which translates into less scar tissue and fibrosis. In diabetic models, Tβ4 treatment has improved motor and sensory nerve conduction velocities, accelerated re-epithelialization, increased vascularization, and enhanced cell viability through pathways including PI3K/AKT and vascular endothelial growth factor signalling.

The review details how Tβ4 manipulates several key signalling cascades relevant to diabetic wounds. It prevents the transcription factor NF-κB from entering the cell nucleus, thereby lowering production of pro-inflammatory molecules such as interleukin-8. It bolsters antioxidant defences by enhancing superoxide dismutase and catalase activity while suppressing tumor necrosis factor alpha and interleukin-6, partly through modulation of the NADPH oxidase system and activation of the Nrf2 pathway. It increases Angiopoietin-1 expression and stabilizes newly formed blood vessels via the Ang1/Tie2 axis, and it activates Wnt/β-catenin signalling to enhance endothelial cell migration, proliferation, and angiogenesis. Through PI3K/AKT signalling, Tβ4 stimulates endothelial nitric oxide synthase, boosting nitric oxide production, vasodilation, and blood flow to healing tissue. Studies in human umbilical vein endothelial cells have also shown that Tβ4 pretreatment reduces harmful reactive oxygen species, restores VEGF expression, and activates insulin-like growth factor 1 signalling, protecting cells from high-glucose toxicity.

Selenium, for its part, is an essential trace element with potent antioxidant, antibacterial, and anti-inflammatory properties. As a coenzyme component of glutathione peroxidase, it neutralizes reactive oxygen species, reduces lipid peroxidation, and lowers neutrophil infiltration into wounds—effects reflected in decreased malondialdehyde and myeloperoxidase levels. Selenium supplementation has been shown to restore extracellular superoxide dismutase and VEGF levels within diabetic ulcers, both essential for angiogenesis and oxidative stress control. Novel delivery platforms are extending these effects: selenium-treated exosomes derived from mesenchymal stem cells have reduced inflammation and enhanced pro-angiogenic activity in endothelial cells, while chitosan-nano selenium biofilms have improved full-thickness wound regeneration in diabetic models. Organo-selenium bandages have even been shown to inhibit bacterial biofilm formation, directly tackling one of the most stubborn obstacles to healing infected ulcers.

The molecular logic of the proposed combination is where the review becomes particularly compelling. Both agents converge on the same central pathways. In the PI3K/AKT cascade, Tβ4 activates signalling to promote cell survival and migration, while selenium enhances Akt phosphorylation through selenoprotein-mediated redox regulation—together amplifying anti-apoptotic and pro-survival signals. On the inflammatory front, selenium-containing glutathione peroxidases suppress NF-κB activation through their antioxidant activity, complementing Tβ4’s direct inhibition of NF-κB nuclear translocation, potentially producing a stronger anti-inflammatory effect in the wound environment than either agent could achieve alone. In the JAK/STAT pathway, Tβ4 modulates STAT3 activation to influence cell proliferation and migration, while selenium affects JAK2/STAT3 signalling through redox-sensitive mechanisms. Both also touch the Wnt/β-catenin pathway, suggesting combined effects on stem cell activation, tissue regeneration, and wound re-epithelialization.

The synergy extends beyond pathway overlap. Tβ4 upregulates VEGF expression and promotes endothelial cell differentiation, while selenium protects those newly formed vessels from oxidative damage by activating Nrf2. Selenium’s ability to modulate matrix metalloproteinases may complement Tβ4’s regulation of actin cytoskeleton reorganization, potentially improving wound contraction and remodelling. The review also highlights metabolic benefits: Tβ4 treatment lowers total cholesterol, triglycerides, and LDL cholesterol while raising HDL cholesterol, and both agents have been linked to improved insulin sensitivity. Selenium supplementation in patients with type 2 diabetes has reduced oxidative stress markers and improved glucose homeostasis and lipid profiles, meaning the combination might address not just the wound but the underlying diabetic pathophysiology that keeps wounds from closing.

Safety data offer cautious encouragement. A phase 1 study of recombinant human thymosin beta 4 (NL005) in healthy volunteers found adverse events were generally mild to moderate, with no serious toxicities and dose-proportional plasma concentrations. Topical Tβ4 in patients with venous stasis ulcers was well tolerated at all doses, with a 0.03 percent concentration showing the highest healing rate and a significantly reduced median healing time compared with placebo. But selenium is a double-edged sword: the review notes that blood levels exceeding roughly 140 nanograms per millilitre are extremely toxic to humans, causing selenosis and potential neurological damage, and excessive doses can paradoxically elevate pro-inflammatory cytokines such as interleukin-6 and tumor necrosis factor alpha, slowing healing. Individual variability in response to Tβ4 and concerns about long-term effects also warrant further study.

The authors are careful to stress that the synergy between Tβ4 and selenium remains theoretical; no study has yet directly tested the combination in diabetic ulcers. They propose a research roadmap beginning with in vitro experiments combining the two agents in cell cultures to assess effects on fibroblast migration, keratinocyte proliferation, and inflammatory markers, followed by animal studies in diabetic wound models measuring wound closure time, angiogenesis, inflammation resolution, and infection control. Only then would well-structured clinical trials establish safety, efficacy, and optimal dosing ratios in patients with chronic diabetic ulcers. Key challenges include defining the optimal Tβ4-to-selenium ratio, managing selenium toxicity—particularly in patients with compromised renal function—and developing delivery systems that maintain the stability and bioavailability of both compounds at the wound site. If those hurdles can be cleared, the reviewers argue, the combination could reduce amputation rates, accelerate healing, and ease the enormous economic burden of diabetic foot ulcers, offering a genuinely integrated attack on a wound that has defeated conventional medicine for decades.

Subject of Research: Combined therapeutic effects of thymosin beta 4 and selenium on diabetic ulcer wound healing

Article Title: The combined impact of thymosin beta 4 and selenium on diabetic ulcers: a comprehensive review

Article References: Srinivasan, K., Sureshkumar, R., Nellore, J., Muthaiah, B., Selvan Christyraj, J. R. S., & Chandrasekaran, V. N. (2025). The combined impact of thymosin beta 4 and selenium on diabetic ulcers: a comprehensive review. Discover Biotechnology, 2(1), Article 11. https://doi.org/10.1007/s44340-025-00015-0

Image Credits: AI Generated

DOI: 10.1007/s44340-025-00015-0

Keywords: thymosin beta 4, selenium, diabetic ulcers, wound healing, angiogenesis, oxidative stress, NF-kB, PI3K/AKT pathway, inflammation, insulin sensitivity, diabetic neuropathy, nanoparticles